Xiao-Dong Zhuang, Fei-Fei Li, Zhan-Peng Wen, Xin-Xue Liao, Zhi-Min Du
Department of Cardiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, P. R. China.
Department of Cardiology, the First Affiliated Hospital of Sun Yat-sen University, No. 58, ZhongShan Er Road, Guangzhou 510080, P. R. China
Ther Adv Cardiovasc Dis. 2016 Jun;10(3):172-7. doi: 10.1177/1753944716648851. Epub 2016 May 15.
The percutaneous coronary intervention (PCI) procedure has become one of the pivotal options in the treatment of coronary artery disease (CAD). Although the PCI procedure has rapidly developed in China, some concerns including in-stent restenosis and dissatisfactory long-term prognosis remain unsolved. Large-scale randomized controlled clinical trials indicate that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) can reduce all-cause mortality and recurrent cardiac events in patients with CAD. ACEIs/ARBs are recommended as a fundamental treatment in the secondary prevention of CAD and reduce in-stent restenosis after PCI. This review focuses on the role of ACEIs/ARBs in improving long-term prognosis and reducing in-stent restenosis.
经皮冠状动脉介入治疗（PCI）已成为冠心病（CAD）治疗的关键选择之一。尽管PCI在中国发展迅速，但一些问题，包括支架内再狭窄和不尽人意的长期预后，仍未得到解决。大规模随机对照临床试验表明，血管紧张素转换酶抑制剂（ACEIs）和血管紧张素II受体阻滞剂（ARBs）可降低CAD患者的全因死亡率和心脏事件复发率。ACEIs/ARBs被推荐作为CAD二级预防的基本治疗方法，并可减少PCI术后的支架内再狭窄。本综述重点关注ACEIs/ARBs在改善长期预后和减少支架内再狭窄方面的作用。
